Consumer medicine information




Brand name


Active ingredient





Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Mogadon.

What is in this leaflet

This leaflet answers some common questions about Mogadon. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Mogadon against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What Mogadon is used for

Mogadon is used to treat sleeping problems, also called insomnia.

Mogadon contains the active ingredient nitrazepam, a benzodiazepine. It is thought to work by its action on brain chemicals.

In general, benzodiazepines such as Mogadon should be taken for short periods only (for example 2 4 weeks). Continuous long-term use is not recommended unless advised by your doctor. The use of benzodiazepines may lead to dependence on the medicine.

This medicine is available only with a doctor's prescription.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed it for another purpose.

Before you take Mogadon

When you must not take it

  1. Do not take Mogadon if you have an allergy to:
  • nitrazepam or any of the ingredients listed at the end of this leaflet
  • any other medicine from the benzodiazepine group of medicines such as diazepam, temazepam, oxazepam, alprazolam and clonazepam.
Some of the symptoms of an allergic reaction may include skin rash, itching or hives.
  1. You have severe and chronic lung disease (e.g. chronic obstructive airway disease) and have difficulty breathing.
  2. You have a severe liver disorder.

Do not take the tablets if the packaging is torn or shows signs of tampering.

Do not take the medicine after the expiry date (EXP) printed on the pack. If you take it after the expiry date has passed, it may not work as well.

Do not give this medicine to children unless advised by the child's doctor. The safety and effectiveness of this medicine in children have not been established.

Before you start to take it

You must tell your doctor if:

  1. You have allergies to
  • any other medicines
  • any other substances, such as foods, preservatives or dyes
  1. You are pregnant or plan to become pregnant.
Your doctor will discuss the risks and benefits of taking this medicine during pregnancy.
  1. You are breastfeeding or plan to breastfeed.
Your doctor will discuss the risks and benefits of taking this medicine when breastfeeding.
  1. You have or have had any other medical conditions including:
  • liver, kidney or lung disease
  • if you suffer from fits or convulsions
  • if you suffer from severe muscle weakness known as myasthenia gravis
  • if you have high or low blood pressure
  • if you have glaucoma (high pressure in the eye)
  • if you suffer from depression, psychosis or schizophrenia
  1. You drink alcohol regularly.
Alcohol may increase the effects of this medicine.
  1. You have a history of falling or are unsteady when walking.

If you have not told your doctor about any of the above, tell them before you take any Mogadon.

Taking other medicines

Tell your doctor if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with each other. These include:

  • other sleeping tablets, sedatives or tranquillisers
  • medicines for depression
  • medicines for allergies for example antihistamines or cold tablets
  • pain relievers
  • muscle relaxants
  • medicines to control fits
  • cimetidine, a medicine used to treat ulcers and reflux
  • disulfiram, a medicine used to deter the consumption of alcohol.

These medicines may increase the effects of Mogadon or be affected by it. You may need to take different amounts of your medicine or you may need to take different medicines. Your doctor will advise you.

Your doctor or pharmacist may have more information on medicines to be careful with or avoid while taking Mogadon.

How to take Mogadon

How much to take

The dose of Mogadon may be different for each person. Your doctor will decide the right dose for you.

The usual adult dose of Mogadon is between 5 to 10 mg (one to two tablets).

For the elderly, the usual dose of Mogadon is 2.5 mg to 5 mg (half to one tablet).

How to take it

Swallow Mogadon whole with a full glass of water.

When to take it

Take the tablet before going to bed.

How long to take it

Do not use Mogadon for longer than your doctor says.

Mogadon is usually taken for short periods only (for example 2 - 4 weeks). Continuous long-term use is not recommended unless advised by your doctor. The use of benzodiazepines may lead to dependence on the medicine.

If you forget to take it

If you forget to take Mogadon before you go to bed and you wake up late in the night or early morning, do not take any Mogadon as you may have trouble waking in the morning. If you have any questions about this, ask your doctor or pharmacist.

If you have trouble remembering when to take your medicine, ask your pharmacist for some hints.

If you take too much (overdose)

Immediately telephone your doctor or the Poisons Information Centre (telephone 13 11 26) for advice, or go to Accident and Emergency at the nearest hospital, if you think that you or anyone else may have taken too much Mogadon. Do this even if there are no signs of discomfort or poisoning. Report any other medicine or alcohol, which has been taken. You may need urgent medical attention. Keep telephone numbers for these places handy.

If you take too much Mogadon the mild symptoms are drowsiness, mental confusion and lethargy. In more serious cases, symptoms are inability to move, loss of muscle tone, hypotension, breathing difficulties, coma and very rarely death.

While you are taking Mogadon

Things you must do

Use Mogadon exactly as your doctor has prescribed.

Tell all doctors, dentists and pharmacists who are treating you that you are taking Mogadon especially if you are about to be started on any new medicines.

If you become pregnant while you are taking Mogadon, tell your doctor immediately.

Tell your doctor if you feel Mogadon is not helping your condition.

Visit your doctor regularly. Your doctor needs to check your progress and see whether you need to keep taking Mogadon.

Always discuss with your doctor any problems or difficulties during or after taking Mogadon.

Tell your doctor if, for any reason, you have not taken your medicine exactly as prescribed. Otherwise your doctor may think that it was not effective and change your treatment unnecessarily.

Keep enough Mogadon to last weekends and holidays.

Things you must not do

Do not drive or operate machinery until you know how Mogadon affects you. Mogadon causes drowsiness and affects alertness in most people.

Make sure you know how you react to Mogadon before you drive a car, operate machinery, or do anything else that could be dangerous if you are drowsy, dizzy or not alert.

Even if you take Mogadon at night, you may still be drowsy or dizzy the next day.

Do not take Mogadon for a longer time than your doctor has prescribed.

Do not stop taking Mogadon or change your dose, without first checking with your doctor. Stopping this medicine suddenly may cause some unwanted effects. Your doctor will slowly reduce your dose of Mogadon before you can stop taking it completely.

Do not suddenly stop taking Mogadon if you suffer from epilepsy. Stopping this medicine suddenly may make your epilepsy worse.

Do not use this medicine to treat any other complaints unless your doctor says to.

Do not give Mogadon to anyone else, even if their symptoms seem similar to yours.

Things to be careful of

Be careful when drinking alcohol while you are taking Mogadon. Combining Mogadon and alcohol can make you more sleepy, dizzy, lightheaded or increase the risk of sleep disorders.

Your doctor may suggest that you avoid alcohol or reduce the amount of alcohol you drink while you are taking Mogadon.

You should not take Mogadon if you experience complex sleep behaviours such as sleep walking, sleep driving or any other bizarre sleep-related behaviours.

Be careful if you are elderly, unwell or taking other medicines. Some people may experience side effects such as drowsiness, confusion, dizziness and unsteadiness. These may increase the risk of a fall.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using Mogadon. Mogadon helps most people with insomnia, but it may have unwanted side effects in some people.

All medicines may have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor if you notice any of the following and they worry you:

  • drowsiness
  • dizziness
  • fatigue
  • confusion
  • unsteadiness when walking
  • impairment of memory
  • headache
  • hangover feeling in the morning
  • slurred speech
  • clumsiness, lack of coordination, numbed emotions
  • reduced alertness
  • muscle weakness
  • double vision
  • inattention
  • unpleasant dreams
  • rebound insomnia.

These side effects are usually mild.

Tell your doctor immediately, or go to Accident and Emergency at your nearest hospital, if you notice any of the following:

  • swelling of the tongue or throat
  • difficulty in breathing.

Tell your doctor if you notice anything else that is making you feel unwell when you are taking, or soon after you have finished taking Mogadon. Other side effects not listed above may occur in some patients.

Like other medicines, Mogadon can cause some side effects. If they occur, they are most likely to be minor and temporary. However, some may be serious, such as complex sleep behaviours, and need medical attention.

Tell your doctor if you notice any unusual changes in your sleep behaviour. Some people may get other side effects while using Mogadon.

Ask your doctor or pharmacist if you don't understand anything in this list.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

After using Mogadon


Keep your tablets in their blister pack until it is time to take them. If you take the tablets out of the blister pack they may not keep well.

Keep Mogadon in a cool dry place where the temperature stays below 30°C. Protect from light. Do not store it or any other medicine in the bathroom or near a sink. Do not leave it in the car or on window sills. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.


If your doctor tells you to stop taking Mogadon or the tablets have passed their expiry date, ask your pharmacist what to do with any tablets left over.

Product description

What Mogadon looks like

Mogadon tablets are white, marked ICN on the upper face and a single break bar on the lower face.

Mogadon comes in a blister pack containing 25 tablets.


Mogadon contains 5mg nitrazepam. Mogadon also contains lactose, starch - maize and magnesium stearate.

Mogadon does not contain gluten, sucrose, tartrazine or any other azo dyes.


iNova Pharmaceuticals (Australia) Pty Limited
ABN: 13 617 871 539
Level 10, 12 Help Street
Chatswood NSW 2067
Tel: 1800 630 056

®= Registered Trademark

AUST R 13751

Date of last amendment: December 2017.

Published by MIMS February 2018


Brand name


Active ingredient





1 Name of Medicine


2 Qualitative and Quantitative Composition

Nitrazepam 5 mg tablets.
Mogadon tablets contain lactose. For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Cylindrical, biplanar, white tablet. Imprint - upper face: "ICN" and two arcs, lower face: single break bar.

4 Clinical Particulars

4.1 Therapeutic Indications

Insomnia, organic and inorganic in origin.

4.2 Dose and Method of Administration


1 to 2 tablets (5 to 10 mg) before retiring. This average dosage may be increased if necessary up to 20 mg for in-patients.

Elderly patients.

½ to 1 tablet.


Not recommended.

4.3 Contraindications

Patients with known hypersensitivity to benzodiazepines.
Patients with chronic obstructive airway disease with incipient respiratory failure.
Patients with severe hepatic insufficiency.

4.4 Special Warnings and Precautions for Use


Although hypotension has occurred only rarely, Mogadon should be administered with caution to patients in whom a drop in blood pressure might lead to cardiac or cerebral complications. This is particularly important in elderly patients (see Section 4.4, Use in the elderly).


Transient amnesia or memory impairment has been reported in association with the use of benzodiazepines.

Myasthenia gravis.

Mogadon could increase the muscle weakness in myasthenia gravis and should be used with caution in this condition.

Acute narrow angle glaucoma.

Caution should be used in the treatment of patients with acute narrow-angle glaucoma (because of atropine-like side effects).

Blood dycrasias.

In rare instances some patients taking benzodiazepines have developed blood dyscrasias. As with other benzodiazepines periodic blood counts are recommended.

Depression, psychosis and schizophrenia.

Mogadon is not recommended as primary therapy in patients with depression and/or psychosis. In such conditions psychiatric assessment and supervision are necessary if benzodiazepines are indicated. Benzodiazepines may increase depression in some patients and may contribute to deterioration in severely disturbed schizophrenics with confusion and withdrawal. Suicidal tendencies may be present or uncovered and protective measures may be required.

Paradoxical reactions.

Paradoxical reactions such as restlessness, agitation, irritability aggressiveness, delusion, nightmares, psychoses, inappropriate behaviour and other adverse behavioural effects, acute rage, stimulation or excitement may occur. Should such reactions occur, Mogadon should be discontinued.

Impaired respiratory function.

Caution in the use of Mogadon is recommended in patients with respiratory depression. In patients with chronic obstructive pulmonary disease, benzodiazepines can cause increased arterial carbon dioxide tension and decreased oxygen tension.


Abrupt withdrawal of benzodiazepines in persons with convulsive disorders may be associated with a temporary increase in the frequency and/or severity of seizures.


Caution must be exercised in administering Mogadon to individuals known to be addiction prone or those whose history suggests they may increase the dosage on their own initiative. It is desirable to limit repeat prescription without adequate medical supervision.

Dependence and tolerance.

The use of benzodiazepines may lead to dependence, as defined by the presence of a withdrawal syndrome on discontinuation of the drug. Tolerance, as defined by a need to increase the dose in order to achieve the same therapeutic effect, seldom occurs in patients receiving recommended doses under medical supervision. Tolerance to sedation may occur with benzodiazepines, especially in those with drug seeking behaviour.

Duration of treatment.

In general, benzodiazepines should be prescribed for short periods only (e.g. 2-4 weeks) see Section 4.2 Dose and Method of Administration. Continuous long-term use of Mogadon is not recommended. There is evidence that tolerance develops to the sedative effects of benzodiazepines. After as little as one week of therapy, withdrawal symptoms can appear following the cessation of recommended doses (e.g. rebound insomnia following cessation of a hypnotic benzodiazepine).


Withdrawal symptoms similar in character to those noted with barbiturates and alcohol have occurred following abrupt discontinuation of benzodiazepines. These symptoms range from insomnia, anxiety, dysphoria, palpitations, panic attacks, vertigo, myoclonus, akinesia, hypersensitivity to light, sound and touch, abnormal body sensations (e.g. feeling of motion, metallic taste), depersonalisation, derealisation, delusional beliefs, hyperreflexia and loss of short term memory, to a major syndrome which may include convulsions, tremor, abdominal and muscle cramps, confusional state, delirium, hallucinations, hyperthermia, psychosis, vomiting and sweating. Such manifestations of withdrawal, especially the more serious ones, are more common in patients who have received excessive doses over a prolonged period. However, withdrawal symptoms have been reported following abrupt discontinuation of benzodiazepines taken continuously at therapeutic levels. Accordingly, Mogadon should be terminated by tapering the dose to minimise occurrence of withdrawal symptoms. Patients should be advised to consult with their physician before either increasing the dose or abruptly discontinuing the medication.
Rebound phenomena have been described in the context of benzodiazepine use. Rebound insomnia and anxiety mean an increase in the severity of these symptoms beyond pre-treatment levels following cessation of benzodiazepines. Rebound phenomena in general possibly reflect re-emergence of pre-existing symptoms combined with withdrawal symptoms described earlier. Some patients prescribed benzodiazepines with very short half-lives (in the order of 2 to 4 hours) may experience relatively mild rebound symptoms in between their regular doses. Withdrawal/rebound symptoms may follow high doses for relatively short periods.

Dose tapering.

Following the prolonged use of Mogadon at therapeutic doses, withdrawal from the medication should be gradual. An individualised timetable should be planned for each patient in whom dependence is known or suspected. Periods from four weeks to four months have been suggested. As with other benzodiazepines when treatment is suddenly withdrawn, a temporary increase in sleep disturbance can occur after use of Mogadon (see Section 4.4 Special Warnings and Precautions for Use, Dependence and tolerance).

Somnambulism and associated behaviours.

Complex behaviours have been reported with sedative hypnotics. These events can occur in sedative-hypnotic naïve as well as in sedative-hypnotic experienced persons. These events can occur at normal therapeutic doses, and the risk appears to be increased when sedative-hypnotics are combined with alcohol or other CNS depressants or used at doses exceeding the maximum recommended dose. Discontinuation of sedative-hypnotics should be strongly considered for patients who have reported complex behaviours whilst not fully awake after taking a sedative-hypnotic.


Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics. Some patients have had additional symptoms such as dyspnoea, throat closing, or nausea and vomiting that suggest anaphylaxis. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal and patients should be advised to contact the emergency department of their nearest hospital as soon as possible.

Use in hepatic impairment.

Patients with impaired hepatic function should use benzodiazepine medication with caution and dosage reduction may be advisable. In rare instances some patients have had elevation of liver enzymes. As with other benzodiazepines periodic liver function tests are recommended.

Use in renal impairment.

Patients with impaired renal function should use benzodiazepine medication with caution and dosage reduction may be advisable.

Use in the elderly.

Geriatric or debilitated patients may be particularly susceptible to the sedative effects of benzodiazepines and associated giddiness, ataxia and confusion, which may increase the possibility of a fall.
In elderly, bed-ridden patients, bronchial hypersecretion and excessive salivation leading to aspiration/pneumonia may occur (see Section 4.8 Adverse Effects (Undesirable Effects)).

Paediatric use.

Not approved for use as a hypnotic in children. (See Section 4.8 Adverse Effects (Undesirable Effects)).

Effects on laboratory tests.

Minor EEG changes, usually low voltage fast activity, of no known clinical significance has been reported with benzodiazepine administration.

4.5 Interactions with Other Medicines and Other Forms of Interactions

The benzodiazepines, including Mogadon, produce additive CNS depressant effects when co-administered with other medications which themselves produce CNS depression, e.g. barbiturates, alcohol, sedatives, tricyclic antidepressants, non-selective MAO inhibitors, phenothiazines and other antipsychotics, skeletal muscle relaxants, antihistamines, narcotic analgesics and anaesthetics (see Section 4.4 Special Warnings and Precautions for Use).
Mogadon undergoes oxidative metabolism, and consequently may interact with disulfiram or cimetidine resulting in increased plasma levels of Mogadon. Patients should be observed closely for evidence of enhanced benzodiazepine response during concomitant treatment with either disulfiram or cimetidine; some patients may require a reduction in benzodiazepine dosage.
The anticholinergic effects of other drugs including atropine and similar drugs, antihistamines and antidepressants may be potentiated.
Interactions have been reported between some benzodiazepines and anticonvulsants, with changes in the serum concentration of the benzodiazepine or anticonvulsant. It is recommended that patients be observed for altered responses when benzodiazepines and anticonvulsants are prescribed together, and that serum level monitoring of the anticonvulsant be performed more frequently.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category C)
Benzodiazepines cross the placenta and may cause hypotonia, reduced respiratory function and hypothermia in the newborn infant. Continuous treatment during pregnancy and administration of high doses in connection with delivery should be avoided. Withdrawal symptoms in newborn infants have been reported with this class of drugs.
Caution should be exercised when Mogadon is given to nursing women. Mogadon is excreted in human breast milk and may cause drowsiness and feeding difficulties in the infant.

4.7 Effects on Ability to Drive and Use Machines

As with all patients taking CNS-depressant medications, patients receiving Mogadon should be warned not to operate dangerous machinery or motor vehicles until it is known that they do not become drowsy or dizzy from Mogadon therapy. Abilities may be impaired on the day following use. Patients should be advised that their tolerance for alcohol and other CNS depressants will be diminished and that these drugs should either be eliminated or given in reduced dosage in the presence of Mogadon (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

4.8 Adverse Effects (Undesirable Effects)

Mogadon is usually well tolerated.

More common reactions.

CNS depression including drowsiness, dizziness, fatigue, confusion, ataxia, impairment of memory, headache, hangover feeling in the morning, vertigo, slurred speech, decreased physical performance, numbed emotions, reduced alertness, muscle weakness, double vision and inattention have been reported. Unpleasant dreams and rebound insomnia have also been reported.

Less common reactions.

Rarely hypotension, faintness, palpitation, rash or pruritus, gastrointestinal disturbances, changes in libido.
Very infrequently, paradoxical reactions may occur, e.g. excitement, stimulation, hallucinations, hyperactivity, and insomnia. Depressed or increased dreaming, disorientation, severe sedation, retrograde amnesia, headache, hypothermia, delirium tremens have also been reported.
Hypersecretion of saliva and bronchial mucus has occurred with doses of 0.7 mg/kg/day. In infants and young children, as well as in elderly, bed-ridden patients, bronchial hypersecretion and excessive salivation leading to aspiration/pneumonia may occur.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at

4.9 Overdose


Overdosage of benzodiazepines is usually manifested by degrees of central nervous system depression ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, mental confusion and lethargy. In more serious cases, symptoms may include ataxia, hypotonia, hypotension, respiratory depression, coma, and very rarely, death.


In the management of overdosage with any medication, it should be borne in mind that multiple agents may have been taken.
Activated charcoal may reduce absorption of the drug if given within one to two hours of ingestion. In patients who are not fully conscious or have impaired gag reflex, consideration should be given to administering activated charcoal via a nasogastric tube, once the airway is protected. Cardiac and vital signs monitoring is recommended, along with general symptomatic and supportive measures. Hypotension and respiratory depression should be managed according to general principles.
Haemoperfusion and haemodialysis are not useful in benzodiazepine intoxication. The benzodiazepine antagonist flumazenil may be useful in hospitalised patients for the reversal of acute benzodiazepine effects. Please consult the flumazenil product information prior to usage.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Nitrazepam is a member of the group of benzodiazepine agonists and exhibits sedative, anxiolytic, anticonvulsant and muscle relaxant effects. This is presumed to be the result of facilitating the action in the brain of gamma-aminobutyric acid, an endogenous inhibitor neurotransmitter.
Taken in the evening in recommended doses Mogadon induces sleep lasting 6-8 hours.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties


Nitrazepam is well and fairly rapidly absorbed from the GI tract. There is considerable interindividual variation in the rate of absorption with time to reach peak plasma concentrations following oral administration about 2 hours with a range of 0.5 - 5 hours. The drug crosses the CSF, the placenta and is excreted in milk.
Peak plasma levels following a 10 mg single oral dose are about 68 - 108 nanogram/mL and following a 5 mg single oral dose about 25 - 50 nanogram/mL. Twelve hours after oral administration of 5 mg nitrazepam, blood levels are about 12 - 38 nanogram/mL.


In one study comparing oral with IV administration, bioavailability varied from 53% - 94% (average 78%).


Nitrazepam is lipophilic and readily crosses body membranes.
CSF concentration of nitrazepam is about 10% total plasma level and similar to the protein free fraction in plasma. One study observed accumulation of nitrazepam in the CSF.
Nitrazepam is found in saliva at lower concentrations than protein free levels in serum.
Nitrazepam has been shown to cross the placenta and reach concentrations between 50 and 90% of the concentration in maternal plasma. It is excreted in breast milk.
The volume of distribution has been found to be significantly higher in elderly immobilised patients than in young controls, whereas the volume of distribution in healthy elderly subjects was found to be similar to young healthy subjects.

Protein binding.

Nitrazepam is approximately 87% bound to plasma protein.


Nitrazepam is metabolised to a significant extent by the liver and the primary route of elimination is urinary excretion of these metabolites. Thus, hepatic or renal disease may require alteration of nitrazepam dosage.
The major pathway is conversion to 7-aminonitrazepam and then to 7-acetamido-nitrazepam with subsequent hydroxylation. Opening of the diazepine ring to form 2-amino-5-nitrobenzophenone has also been reported. These metabolites have very weak pharmacological activity.
There is no evidence of nitrazepam dependent enzyme induction or inhibition during long term treatment.
Total plasma clearance has been estimated as 4.1 ± 2.0 litre/hour in young and 4.7 ± 1.5 litre/hour in elderly patients.


Nitrazepam is mainly excreted as urinary metabolites. During the first 120 hours after a single radio-labelled 10 mg oral dose, the total renal elimination was 70%. Only 1% or less of the administered dose is excreted as unchanged nitrazepam.
The main urinary excretion products are free or conjugated 7-amino nitrazepam and 7-acetamido nitrazepam. Individual variation of the total excreted metabolites is high, ranging between 17 and 99% of the administered dose. Of this, the conjugated metabolites made up an average of 57%.
One faecal excretion study indicates the possibility of limited biliary excretion of the metabolites.

Half life.

Nitrazepam is eliminated relatively slowly from the body. Following oral administration, half-life has been estimated to be from 16 to 48 hours, average 27 hours. The half-life in CSF appears to be about twice as long as that in plasma.
Elimination half-life has been estimated to be significantly higher in elderly debilitated patients as opposed to healthy elderly subjects and young subjects.

5.3 Preclinical Safety Data


No data available.


No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Lactose, magnesium stearate, starch - maize.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 30°C. Protect from light.

6.5 Nature and Contents of Container

PVC/PVDC/Aluminium Blister pack: 4's#, 25's, 30's#, 100's#.
# Not currently distributed in Australia.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Chemically nitrazepam is 1,3-dihydro-7-nitro-5-phenyl-2H-1-benzodiazepine-2 one. It is a pale yellow, crystalline substance, insoluble in water. It has a molecular weight of 281.27.

Chemical structure.

CAS number.


7 Medicine Schedule (Poisons Standard)


Summary Table of Changes